Whereas 89.5% of new prescriptions for disease-modifying anti-rheumatic drugs (DMARDs) in 2000 were for old-line agents, by ...

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve ...

with adalimumab becoming the most commonly used b/tsDMARD. Researchers performed a serial cross-sectional study using ...

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

Despite gastroenterologists' tendency to embrace biosimilar treatment options, the use of biosimilar adalimumab versus branded Humira remains comparable across specialties. AbbVie’s Humira ...

Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However, the lackluster performance of the US biosimilar ...

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.

A recent post hoc analysis of the EXXELERATE study revealed that certolizumab pegol (CZP) sustained drug concentration and ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

A biologic can target a very specific part of your immune system. For example, the TNF-blocker Humira (adalimumab) works by controlling the effects of tumor necrosis factor (TNF), a protein made by ...